Welcome to our dedicated page for Deciphera Pharma news (Ticker: DCPH), a resource for investors and traders seeking the latest updates and insights on Deciphera Pharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Deciphera Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Deciphera Pharma's position in the market.
Deciphera Pharmaceuticals (NASDAQ:DCPH) announced clinical data for QINLOCK, a tyrosine kinase inhibitor for fourth-line gastrointestinal stromal tumor (GIST), presented at CTOS 2020. Key findings include a median progression-free survival (PFS) of 6.3 months for QINLOCK compared to 1 month for placebo, demonstrating a hazard ratio of 0.16. The data highlights the complex mutational landscape of GIST and QINLOCK’s efficacy across various KIT/PDGFRA mutations. Further presentations at the meeting included ongoing Phase 1 studies and follow-up results from INVICTUS, reinforcing QINLOCK's potential in advanced GIST treatment.
Deciphera Pharmaceuticals (NASDAQ:DCPH) announced preliminary results from its ongoing Phase 1/2 study of DCC-3014, a selective oral inhibitor targeting CSF1R for treating tenosynovial giant cell tumor (TGCT). Presented at the CTOS 2020 Virtual Annual Meeting, the data showed an objective response rate of 41% among evaluable patients, with 22 of 25 patients receiving treatment. DCC-3014 was generally well-tolerated, with a recommended Phase 2 dose established at 30 mg twice weekly. The study is expanding to further assess the drug's efficacy and safety in TGCT patients.
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) will have its President and CEO, Steve Hoerter, present at the Jefferies Virtual London Healthcare Conference on November 17 at 9:40 AM ET. A live webcast of the event can be accessed on the Company’s website under the ‘Events and Presentations’ section, and a replay will be available for 90 days post-event. Deciphera focuses on developing innovative cancer treatments, including its FDA-approved drug, QINLOCK, for fourth-line GIST, which holds approvals in Canada and Australia.
Deciphera Pharmaceuticals (NASDAQ:DCPH) reported its third-quarter financial results for 2020, showcasing a strong U.S. commercial launch of QINLOCK. The product generated $15.2 million in net revenue, reflecting successful FDA approval. The company also submitted a Marketing Authorisation Application to the EMA and established distribution agreements in Canada and Australia. However, net loss for the quarter increased to $63.7 million. R&D expenses rose to $49.2 million, driven by clinical trials, while cash reserves improved to $584.3 million, supporting operations into 2022.
Deciphera Pharmaceuticals (NASDAQ:DCPH) will announce its third quarter 2020 financial results on November 5, 2020. Following the earnings release, a live conference call and webcast will take place at 4:30 PM ET to discuss the results and provide corporate updates. Interested parties can join the call via phone or access the webcast on Deciphera's investor website. The archived call will be accessible for 30 days after the event. The company is focused on developing innovative cancer treatments, including its FDA-approved drug, QINLOCK, for certain gastrointestinal tumors.